NCT06089590 (I-CARE 2) is a clinical trial of Non-interventional in IBD, sponsored by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives.

Who is sponsoring NCT06089590?

NCT06089590 is sponsored by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives.

What drugs are being tested in NCT06089590?

Interventions in NCT06089590: Non-interventional.

What condition does NCT06089590 study?

NCT06089590 studies IBD, Ulcerative Colitis, Crohn Disease.

Is NCT06089590 still recruiting?

NCT06089590 is currently recruiting now. Last updated 14 March 2025.

Last reviewed 2025-03-14 · How we verify

NCT06089590: I-CARE 2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ibd CAncer and seRious Infections in France (I-CARE 2)

Recruiting now Last updated 14 March 2025

What this trial tests

trial testing Non-interventional in IBD in 6,000 participants. Currently enrolling.

Timeline

25 January 2024

Primary endpoint
1 March 2031

1 March 2031

Quick facts

Lead sponsor	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	6,000
Start date	25 January 2024
Primary completion	1 March 2031
Estimated completion	1 March 2031
Sites	2 locations across France

Drugs / interventions tested

Non-interventional

Conditions studied

IBD — all drugs for IBD →
Ulcerative Colitis — all drugs for Ulcerative Colitis →
Crohn Disease — all drugs for Crohn Disease →

Sponsor

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives — full company profile →

Who can join

Adults 18 to 75, any sex, with IBD or Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a French prospective longitudinal observational multicentre cohort study. Primary objective : to assess prospectively the presence and the extent of safety concerns (cancer, serious infections, arterial and venous thrombotic events) in patients with CD and UC and treated with JAKi, anti-IL23p19, and S1p modulators.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease.
Tian Z, Zhao Q, Teng X. · · 2024 · cited 13× · PMID 39086483 · DOI 10.3389/fimmu.2024.1393463

Verify or expand the search:

Other trials of Non-interventional

Trials testing the same drug.

NCT06798298 — A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells · recruiting
NCT06746883 — A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacte · recruiting
NCT06622798 — Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients · recruiting
NCT06784154 — The Role of Ectopic Fat and Heart Attack Risk in HIV · recruiting
NCT06277037 — Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) · recruiting

Other recruiting trials for IBD

Currently open trials in the same condition.

NCT07385807 — Exploring Fecal Calprotectin Levels, Maternal and Infant Microbiota, Infant Health, Nutrition, and Adverse Pregnancy Out · recruiting
NCT07271264 — A Randomised Paired Design Study of Texture and Colour Enhancement Imaging (TXI) Versus High-definition White Light Endo · NA · recruiting
NCT07224113 — Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD · recruiting
NCT07195123 — Evaluation of the SMART IBD App in Pediatric IBD · NA · recruiting
NCT07380022 — Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Def · NA · recruiting

Other Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives trials

Trials by the same sponsor.

NCT06742385 — Evaluation of a Remote Monitoring Application in the Follow-up of Patients With Active Inflammatory Bowel Diseases · NA · recruiting
NCT06250361 — Identification of Factors ASsociaTed With a Delayed Diagnosis in Crohn's Disease · unknown
NCT05158517 — VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Mu · active not recruiting
NCT05072782 — Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalat · Phase 4 · unknown
NCT04990258 — A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Inflix · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06089590 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Last refreshed: 14 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06089590.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing